Abstract | BACKGROUND:
Weight gain is a frequent side-effect of thiazolidinediones, possibly related to fluid retention and stimulation of pre-adipocyte differentiation. METHODS: RESULTS: All patients had reported previous weight gain following treatment with thiazolidinediones. All patients lost weight over 12 weeks in the program with their mean +/- SD body weight falling from 270 +/- 54 lbs (123 +/- 25 kg) to 244 +/- 61 lbs (111 +/- 28 kg) (p < 0.01). The weight loss observed was no different from that observed in 16 age- and gender-matched patients with type 2 diabetes not treated with thiazolidinediones (from 263 +/- 54 lbs (120 +/- 25 kg) to 239 +/- 52 lbs (109 +/- 24 kg); p < 0.01). Glycemic control improved while reducing insulin treatment. Blood pressure control also improved and antihypertensive medications were decreased. The degree and time course of weight loss is no different from that in patients treated with other diabetic therapies and is associated with improved glycemic and blood pressure control. CONCLUSIONS:
|
Authors | Sunil Asnani, Byron C Richard, Cyrus Desouza, Vivian Fonseca |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 19
Issue 7
Pg. 609-13
( 2003)
ISSN: 0300-7995 [Print] England |
PMID | 14606983
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Hypoglycemic Agents
- Thiazolidinediones
|
Topics |
- Adult
- Behavior Therapy
- Body Weight
(drug effects)
- Diet, Reducing
- Energy Intake
- Extracellular Fluid
(drug effects)
- Female
- Humans
- Hypoglycemic Agents
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Thiazolidinediones
(administration & dosage, adverse effects)
- United States
- Weight Loss
|